Khushali S. Jhaveri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Khushali S. Jhaveri has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Kai Rejeski
Memorial Sloan Kettering Cancer Center, New York, New York, United States
31 shared publications - Marion Subklewe
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
31 shared publications - Michael D. Jain
Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL, USA
31 shared publications - Nathan H. Parker
Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
31 shared publications - Christian Schmidt
Department of Medicine III, University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany
18 shared publications - David M. Cordas dos Santos
Center for Early Detection and Interception of Blood Cancers, Dana–Farber Cancer Institute, Boston, USA
18 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
Although CD19-directed chimeric antigen receptor T-cell therapy (CD19.CAR-T) has proven clinical efficacy for multiple refractory B-cell malignancies, over 50% of patients ultimately relapse. Recent evidence has underlined the critical role of the host in determining treatment responses. In this retrospective observational study of 106 patients with relapsed/refractory large B-cell lymphoma receiving standard-of-care CD19.CAR-T, we analyzed the impact of immunometabolic host features and detailed body composition measurements on post–CAR T clinical outcomes. We extracted muscle and adipose tissue distributions from prelymphodepletion CT images and assessed laboratory-based immuno-nutritional scores. Early responders displayed increased total abdominal adipose tissue deposits (TAT: 336 mm3 vs. 266 mm3, P = 0.008) and favorable immuno-nutritional scores compared to nonresponding patients. On univariate Cox regression analysis, visceral fat distribution, sarcopenia, and nutritional indices significantly impacted both progression-free (PFS) and overall survival (OS). Patients with a low skeletal muscle index (SMI; e.g.<34.5), a sarcopenia indicator, exhibited poor clinical outcomes (mOS 3.0 months vs. 17.6 months, log-rank P = 0.0026). Prognostically adverse immuno-nutritional scores were linked to inferior survival [low PNI: HROS, 6.31; 95% confidence interval (CI), 3.35–11.90; P < 0.001]. In a multivariable analysis adjusting for baseline Eastern Cooperative Oncology Group performance status, C-reactive protein, and lactate dehydrogenase, increased TAT was independently associated with improved clinical outcomes (adjusted HROS, 0.27; 95% CI, 0.08–0.90; P = 0.03). We noted particularly favorable treatment outcomes in patients with both increased abdominal fat and muscle mass (TAThigh/SMIhigh: 1-year PFS 50%, 1-year OS 83%). These real-world data provide evidence for a role of body composition and immuno-nutritional status in the context of CD19.CAR-T and suggest that the obesity paradox may extend to modern T cell–based immunotherapies.See related Spotlight by Nawas and Scordo, p. 704
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
Although CD19-directed chimeric antigen receptor T-cell therapy (CD19.CAR-T) has proven clinical efficacy for multiple refractory B-cell malignancies, over 50% of patients ultimately relapse. Recent evidence has underlined the critical role of the host in determining treatment responses. In this retrospective observational study of 106 patients with relapsed/refractory large B-cell lymphoma receiving standard-of-care CD19.CAR-T, we analyzed the impact of immunometabolic host features and detailed body composition measurements on post–CAR T clinical outcomes. We extracted muscle and adipose tissue distributions from prelymphodepletion CT images and assessed laboratory-based immuno-nutritional scores. Early responders displayed increased total abdominal adipose tissue deposits (TAT: 336 mm3 vs. 266 mm3, P = 0.008) and favorable immuno-nutritional scores compared to nonresponding patients. On univariate Cox regression analysis, visceral fat distribution, sarcopenia, and nutritional indices significantly impacted both progression-free (PFS) and overall survival (OS). Patients with a low skeletal muscle index (SMI; e.g.<34.5), a sarcopenia indicator, exhibited poor clinical outcomes (mOS 3.0 months vs. 17.6 months, log-rank P = 0.0026). Prognostically adverse immuno-nutritional scores were linked to inferior survival [low PNI: HROS, 6.31; 95% confidence interval (CI), 3.35–11.90; P < 0.001]. In a multivariable analysis adjusting for baseline Eastern Cooperative Oncology Group performance status, C-reactive protein, and lactate dehydrogenase, increased TAT was independently associated with improved clinical outcomes (adjusted HROS, 0.27; 95% CI, 0.08–0.90; P = 0.03). We noted particularly favorable treatment outcomes in patients with both increased abdominal fat and muscle mass (TAThigh/SMIhigh: 1-year PFS 50%, 1-year OS 83%). These real-world data provide evidence for a role of body composition and immuno-nutritional status in the context of CD19.CAR-T and suggest that the obesity paradox may extend to modern T cell–based immunotherapies.See related Spotlight by Nawas and Scordo, p. 704
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S2: Multivariable Cox fits with HR and 95% CI for NRM.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S2: Multivariable Cox fits with HR and 95% CI for NRM.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S2: Survival and Cumulative Incidence Analysis by Baseline SMI Depletion Categories.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S2: Survival and Cumulative Incidence Analysis by Baseline SMI Depletion Categories.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S6: Association of corticosteroids and SMI loss.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S6: Association of corticosteroids and SMI loss.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 5: Baseline Serum Metabolomic Profiles Associated with Progression and Mortality.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 5: Baseline Serum Metabolomic Profiles Associated with Progression and Mortality.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S5: Summary of clinical variables by SMI loss at day 90.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S5: Summary of clinical variables by SMI loss at day 90.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S7: Comparison of Cytokine expansion in Sarcopenic vs. Non-sarcopenic Individuals and Association with SMI Loss.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S7: Comparison of Cytokine expansion in Sarcopenic vs. Non-sarcopenic Individuals and Association with SMI Loss.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 4: PFS and OS Stratified by Sarcopenia and SMI Loss Status at Day 30 and Day 90.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 4: PFS and OS Stratified by Sarcopenia and SMI Loss Status at Day 30 and Day 90.